Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antidepressant
EVT-103
Другие языки:

    EVT-103

    Подписчиков: 0, рейтинг: 0
    EVT-103
    Clinical data
    Other names ENS-103
    Routes of
    administration    		 By mouth
    Drug class NMDA receptor antagonist
    Identifiers
    CAS Number

    EVT-103, also known as ENS-103, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder. It acts as an NMDA receptor subunit 2B (NR2B) antagonist. As of November 2017, no recent reports of development for major depressive disorder have been identified. The drug was developed as a follow-up compound to EVT-101. The chemical structure of EVT-103 has not been released.

    See also


    Новое сообщение